Oncology

Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)

Thursday, April 2, 2020 - 7:04pm

The EC approval is based on a comprehensive data package which demonstrated biosimilarity of RUXIENCE to the reference product.

Key Points: 
  • The EC approval is based on a comprehensive data package which demonstrated biosimilarity of RUXIENCE to the reference product.
  • Building on our ongoing commitment to bring biosimilars to market, we look forward to making RUXIENCE available to patients in the EU in the coming months.
  • Before starting treatment with RUXIENCE, talk to your doctor, pharmacist or nurse if:
    you have ever had or might now have a hepatitis infection.
  • This is because in a few cases, RUXIENCE could cause hepatitis B to become active again, which can be fatal in very rare cases.

Cancer Vaccine Start Up, Calviri, Closes Successful Seed Funding Round

Thursday, April 2, 2020 - 5:37pm

Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding.

Key Points: 
  • Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding.
  • The funding is from five private investors including Dr. Jacque Sokolov, a Calviri Board member, and Dr. Mitzi Krockover.
  • This process is the basis for the design of off-the-shelf vaccines for any cancer, as well as diagnostics for the early detection of any cancer.
  • Kathryn Sykes, VP of Research and Product Development, stated, We will use the funding to demonstrate the strengths of this unique technology.

Oncology® Welcomes Julie M. Vose, M.D., MBA, and Howard S. Hochster, M.D., FACP, as Co-Editors in Chief

Thursday, April 2, 2020 - 4:27pm

Vose and Hochster join the Oncology team as co-editors in chief, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Oncology.

Key Points: 
  • Vose and Hochster join the Oncology team as co-editors in chief, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of Oncology.
  • She currently serves as the chief of the oncology/hematology division in the Department of Internal Medicine at UNMC and Oncology Chief for Nebraska Medicine.
  • Vose and Hochster will bring to our network of health care professionals in the oncology space, said Kristie Kahl, editorial director of Oncology.
  • Vose and Hochster will aid Oncology in delivering top-tier content and broaden the variety of oncology topics covered.

Texas Oncology Expands Telemedicine Services

Thursday, April 2, 2020 - 4:00pm

Texas Oncology announced today a major expansion of its telemedicine services to allow patients to schedule virtual visits with more than 400 physicians and 150 advanced practice providers throughout the statewide cancer care practice.

Key Points: 
  • Texas Oncology announced today a major expansion of its telemedicine services to allow patients to schedule virtual visits with more than 400 physicians and 150 advanced practice providers throughout the statewide cancer care practice.
  • Texas Center for Proton Therapy, Texas Breast Specialists and Texas Urology Specialists, which are part of Texas Oncology, also are participating in the telemedicine initiative.
  • To find out if your case is appropriate for Texas Oncologys telemedicine capability, contact your Texas Oncology location for more information .
  • Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery.

New Study Shows Benefit of Using Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer

Thursday, April 2, 2020 - 2:15pm

This report builds upon a fast-growing body of scientific evidence behind the Signatera test across multiple cancer types.

Key Points: 
  • This report builds upon a fast-growing body of scientific evidence behind the Signatera test across multiple cancer types.
  • The study follows a 72-year old man with recurrent Stage III esophageal cancer whose recurrence was detected 350 days before radiographic imaging, using Signatera's personalized and tumor-informed technology.
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

Hope4Cancer™ Treatment Centers To Launch 'Eight Days,' A Novel Reality Show About Alternative Ways To Fight Cancer

Thursday, April 2, 2020 - 1:00pm

Hope4Cancer Treatment Centers announces Eight Days, a groundbreaking reality TV series that tells the stories of five cancer survivors and their journey using integrative cancer treatments that are working.

Key Points: 
  • Hope4Cancer Treatment Centers announces Eight Days, a groundbreaking reality TV series that tells the stories of five cancer survivors and their journey using integrative cancer treatments that are working.
  • The first reality TV series of its kind,Eight Days,is set to premiere on the WGN Network, on Sunday, April 5, 2020.
  • From physical, emotional, and spiritual healing, as well as, how to treat the root of cancer instead of the symptoms.
  • But being a parent, I've taken the gloves off, and I'm ready to fight this," says Kate Malvenan, cancer patient, Eight Days.

Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier

Thursday, April 2, 2020 - 2:00pm

VBL and NanoCarrier Co. Ltd. signed an exclusive license agreement in 2017 for the development, commercialization, and supply of VB-111 in Japan.

Key Points: 
  • VBL and NanoCarrier Co. Ltd. signed an exclusive license agreement in 2017 for the development, commercialization, and supply of VB-111 in Japan.
  • There are more than 10,000 women diagnosed with ovarian cancer in Japan with more than 5,000 associated deaths annually.
  • The Data Safety Monitoring Committee (DSMC) overseeing OVAL recently conducted a preplanned interim analysis and recommended that the study continue.
  • We are very pleased that NanoCarrier has chosen to develop VB-111 in ovarian cancer in Japan, said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics.

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate

Thursday, April 2, 2020 - 1:18pm

Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, and Takis Biotech (Takis), a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate.

Key Points: 
  • Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, and Takis Biotech (Takis), a company focused on the development of cancer vaccines and founded by scientists from Merck Research Laboratories, today announce an expansion of their COVID-19 vaccine development program to include a fifth vaccine candidate.
  • Dr. James Hayward, president and CEO of Applied DNA, stated, With the addition of a fifth candidate, we have more arrows in our quiver to enhance our probability of success.
  • The new potential candidate may facilitate a productive immune response, while minimizing mechanisms known to have potential negative effects on the infection.
  • Concurrent with the Takis animal trials, Applied DNA will prepare for cGMP production of selected vaccine candidate(s) to support human trials scheduled to begin this fall.

Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger

Thursday, April 2, 2020 - 1:30pm

Further details about the time, location and record date for the Special Meetings will be announced when finalized.

Key Points: 
  • Further details about the time, location and record date for the Special Meetings will be announced when finalized.
  • We look forward to putting the vote before our stockholders, closing the merger and beginning this exciting next phase of growth for our business.
  • Lantheus and Progenics both remain committed to closing the transaction in the second quarter of 2020 and remain confident in the benefits that the proposed combination will bring to the stockholders of both companies.
  • Lantheus, Progenics, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction.

Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

Thursday, April 2, 2020 - 1:00pm

Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.

Key Points: 
  • Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.
  • The EV-302 trial is evaluating the combination of PADCEV and pembrolizumab with or without chemotherapy versus chemotherapy alone in patients with previously untreated locally advanced or metastatic urothelial cancer.
  • PADCEV was approved under the FDAs Accelerated Approval Program based on tumor response rate.
  • Hyperglycemia occurred in patients treated with PADCEV, including death and diabetic ketoacidosis (DKA), in those with and without pre-existing diabetes mellitus.